Manufacturing issues are the latest problem for Ultragenyx Pharmaceutical Inc. to solve after last week’s disappointment in a phase III study to treat brittle bones. The U.S. FDA gave the company a ...

Ultragenyx Pharmaceuticals took another hit when the FDA rejected its gene therapy for patients with a rare, genetic disorder.

Kenvue stock yo-yoes Monday after the company — known for brands like Tylenol — announced a new CEO and strategic review.

Capricor plans to resubmit its application for the approval of deramiocel for DMD after the FDA declined to accept the ...